Top

Archives of Gynecology and Obstetrics

Published in:

01-01-2016 | Gynecologic Oncology

The prognostic of p27^kip1 in ovarian cancer: a meta-analysis

Authors: Mudan Lu, You Wang, Fei Xu, Jingying Xiang, Daozhen Chen

Published in: Archives of Gynecology and Obstetrics | Issue 1/2016

Abstract

Purpose

P27^kip1 is a negative cell cycle regulator that plays an important role in tumor suppression. Deregulation of p27^kip1 is commonly observed in many human cancers. Numerous studies about p27^kip1 are reported in clinical patients despite variable data for the prognostic of p27^kip1 expression. Here we report a meta-analysis of the association of p27^kip1 expression with the survival of ovarian cancer.

Methods

PubMed and Web of science were searched for studies evaluating expression of p27^kip1 and prognostic in ovarian cancer. Published data were extracted and computed into odds ratios (ORs) for death at 3 and 5 years. Data were pooled using the random-effect model. All statistical tests were two-sided.

Results

Analysis included 9 studies: six studies were reported in European, three studies were reported in American, and one study was reported in Asian. Loss of p27^kip1 was associated with worse overall survival (OS) at both 3 years [OR = 2.61, 95 % confidence interval (CI) 1.95–3.49, p < 0.05] and 5 years (OR = 3.01, 95 % CI 2.17–4.17, p < 0.05). Among studies with different ethnicity (European, American and Asian), the results showed a more significant association in European, including Italy, Germany, and Greece [for both 3-year OS (OR = 3.53, 95 % CI 2.37–5.26) and 5-year OS (OR = 3.66, 95 % CI 2.30–5.83)].

Conclusions

Loss of p27^kip1 is associated with worse survival in ovarian cancer. The development of strategies target p27^kip1 could be a reasonable therapeutic approach.

Brewer MA, Johnson K, Follen M et al (2003) Prevention of ovarian cancer: intraepithelial neoplasia. Clin Cancer Res 9:20–30PubMed

Bast RC Jr, Urban N, Shridhar V et al (2002) Early detection of ovarian cancer: promise and reality. Cancer Treat Res 107:61–97PubMed

Sanseverino F, Torricelli M, Petraglia F et al (2003) Role of the retinoblastoma family in gynecological cancer. Cancer Biol Ther 2:636–641PubMedCrossRef

Zhang D, Vuocolo S, Masciullo V et al (2001) Cell cycle genes as targets of retinoid induced ovarian tumor cell growth suppression. Oncogene 20:7935–7944PubMedCrossRef

Bali A, O’Brien PM, Edwards LS et al (2004) Cyclin D1, p53, and p21Waf1/Cip1 expression is predictive of poor clinical outcome in serous epithelial ovarian cancer. Clin Cancer Res 10:5168–5177PubMedCrossRef

Masciullo V, Ferrandina G, Pucci B et al (2000) p27^kip1expression is associated with clinical outcome in advanced epithelial ovarian cancer: multivariate analysis. Clin Cancer Res 6:4816–4822PubMed

Hashimoto T, Yanaihara N, Okamoto A et al (2011) Cyclin D1 predicts the prognosis of advanced serous ovarian cancer. Exp Ther Med 2:213–219PubMedPubMedCentral

Hurteau JA, Allison BM, Brutkiewicz SA et al (2001) Expression and subcellular localization of the cyclin-dependent kinase inhibitor p27(Kip1) in epithelial ovarian cancer. Gynecol Oncol 83:292–298PubMedCrossRef

Masciullo V, Sgambato A, Pacilio C et al (1999) Frequent loss of expression of the cyclin-dependent kinase inhibitor p27 in epithelial ovarian cancer. Cancer Res 59:3790–3794PubMed

10.

Farley J, Smith LM, Darcy KM et al (2011) Nuclear P27 expression in benign, borderline (LMP) and invasive tumors of the ovary and its association with prognosis: a gynecologic oncology group study. Gynecol Oncol 121:395–401PubMedCrossRef

11.

Schmider-Ross A, Pirsig O, Gottschalk E et al (2006) Cyclin-dependent kinase inhibitors CIP1 (p21) and KIP1 (p27) in ovarian cancer. J Cancer Res Clin Oncol 132:163–170PubMedCrossRef

12.

Psyrri A, Bamias A, Yu Z et al (2005) Subcellular localization and protein levels of cyclin-dependent kinase inhibitor p27 independently predict for survival in epithelial ovarian cancer. Clin Cancer Res 11:8384–8390PubMedCrossRef

13.

Rosen DG, Yang G, Cai KQ et al (2005) Subcellular localization of p27kip1 expression predicts poor prognosis in human ovarian cancer. Clin Cancer Res 11:632–637PubMed

14.

Korkolopoulou P, Vassilopoulos I, Konstantinidou AE et al (2002) The combined evaluation of p27Kip1 and Ki-67 expression provides independent information on overall survival of ovarian carcinoma patients. Gynecol Oncol 85:404–414PubMedCrossRef

15.

Parmar MK, Torri V, Stewart L (1998) Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17:2815–2834PubMedCrossRef

16.

Tsihlias J, Kapusta LR, DeBoer G et al (1998) Loss of cyclin-dependent kinase inhibitor p27Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Res 58:542–548PubMed

17.

Slingerland JM, Hengst L, Pan CH et al (1994) A novel inhibitor of cyclin-Cdk activity detected in transforming growth factor beta-arrested epithelial cells. Mol Cell Biol 14:3683–3694PubMedPubMedCentralCrossRef

18.

Polyak K, Lee MH, Erdjument-Bromage H et al (1994) Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 78:59–66PubMedCrossRef

19.

Nakayama K, Ishida N, Shirane M et al (1996) Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 85:707–720PubMedCrossRef

20.

Fero ML, Rivkin M, Tasch M et al (1996) A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice. Cell 85:733–744PubMedCrossRef

21.

Muraoka RS, Lenferink AE, Simpson J et al (2001) Cyclin-dependent kinase inhibitor p27(Kip1) is required for mouse mammary gland morphogenesis and function. J Cell Biol 153:917–932PubMedPubMedCentralCrossRef

22.

McAllister SS, Becker-Hapak M, Pintucci G et al (2003) Novel p27(kip1) C-terminal scatter domain mediates Rac-dependent cell migration independent of cell cycle arrest functions. Mol Cell Biol 23:216–228PubMedPubMedCentralCrossRef

23.

Duncan TJ, Al-Attar A, Rolland P et al (2010) Cytoplasmic p27 expression is an independent prognostic factor in ovarian cancer. Int J Gynecol Pathol 29:8–18PubMedCrossRef

24.

Sims AH, Zweemer AJ, Nagumo Y et al (2012) Defining the molecular response to trastuzumab, pertuzumab and combination therapy in ovarian cancer. Br J Cancer 106:1779–1789PubMedPubMedCentralCrossRef

25.

Turner JG, Dawson J, Sullivan DM (2012) Nuclear export of proteins and drug resistance in cancer. Biochem Pharmacol 83:1021–1032PubMedPubMedCentralCrossRef

26.

Le XF, Mao W, He G et al (2011) The role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cells. J Natl Cancer Inst 103:1403–1422PubMedPubMedCentralCrossRef

27.

Li CF, Wang JM, Kang HY et al (2012) Characterization of gene amplification-driven SKP2 overexpression in myxofibrosarcoma: potential implications in tumor progression and therapeutics. Clin Cancer Res 18:1598–1610PubMedCrossRef

28.

Hershko DD (2010) Cyclin-dependent kinase inhibitor p27 as a prognostic biomarker and potential cancer therapeutic target. Future Oncol 6:1837–1847PubMedCrossRef

29.

Zhao H, Bauzon F, Fu H et al (2013) Skp2 deletion unmasks a p27 safeguard that blocks tumorigenesis in the absence of pRb and p53 tumor suppressors. Cancer Cell 24:645–659PubMedCrossRef

30.

Shi YC, Zhao H, Yin C et al (2013) C/EBPα inhibits hepatocellular carcinoma by reducing Notch3/Hes1/p27 cascades. Dig Liver Dis 45:844–851PubMedCrossRef

31.

Wu X, Liu T, Fang O et al (2013) miR-194 suppresses metastasis of non-small cell lung cancer through regulating expression of BMP1 and p27(kip1). Oncogene. doi:10.1038/onc.2013.108

32.

Mills AM, Ly A, Balzer BL et al (2013) Cell cycle regulatory markers in uterine atypical leiomyoma and leiomyosarcoma: immunohistochemical study of 68 cases with clinical follow-up. Am J Surg Pathol 37:634–642PubMedCrossRef

33.

Fei M, Zhao Y, Wang Y et al (2009) Low expression of Foxo3a is associated with poor prognosis in ovarian cancer patients. Cancer Invest 27:52–59PubMedCrossRef

34.

Levanon K, Sapoznik S, Bahar-Shany K et al (2013) FOXO3a loss is a frequent early event in high-grade pelvic serous carcinogenesis. Oncogene. doi:10.1038/onc.2013.394 PubMedPubMedCentral

35.

Siu MK, Wong ES, Kong DS et al (2013) Stem cell transcription factor NANOG controls cell migration and invasion via dysregulation of E-cadherin and FoxJ1 and contributes to adverse clinical outcome in ovarian cancers. Oncogene 32:3500–3509PubMedCrossRef

36.

Fu G, Peng C (2011) Nodal enhances the activity of FoxO3a and its synergistic interaction with Smads to regulate cyclin G2 transcription in ovarian cancer cells. Oncogene 30:3953–3966PubMedCrossRef

37.

Chock KL, Allison JM, Shimizu Y et al (2010) BRCA1-IRIS overexpression promotes cisplatin resistance in ovarian cancer cells. Cancer Res 70:8782–8791PubMedCrossRef

38.

Kim TH, Lee HH, Chung SH, et al. (2015) Expression of p27 and Jun activation domain-binding protein 1 in endometriosis. Arch Gynecol Obstet. 2015 Feb 10. [Epub ahead of print]

39.

Iwasaki S, Sudo T, Miwa M et al (2013) Endometrial stromal sarcoma: clinicopathological and immunophenotypic study of 16 cases. Arch Gynecol Obstet 288(2):385–391PubMedCrossRef

40.

Hasegawa K, Torii Y, Ishii R, Oe S, Kato R, Udagawa Y (2011) Effects of a selective COX-2 inhibitor in patients with uterine endometrial cancers. Arch Gynecol Obstet 284(6):1515–1521PubMedCrossRef

41.

Konecny GE, Wang C, Hamidi H et al (2014) Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer. J Natl Cancer Inst. doi:10.1093/jnci/dju249 PubMedPubMedCentral

42.

Tothill RW, Tinker AV, George J et al (2008) Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 14:5198–5208PubMedCrossRef

Title: The prognostic of p27kip1 in ovarian cancer: a meta-analysis
Authors: Mudan Lu
You Wang
Fei Xu
Jingying Xiang
Daozhen Chen
Publication date: 01-01-2016
Publisher: Springer Berlin Heidelberg
Published in: Archives of Gynecology and Obstetrics / Issue 1/2016
Print ISSN: 0932-0067
Electronic ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-015-3817-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The prognostic of p27^kip1 in ovarian cancer: a meta-analysis

Abstract

Purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2016

Neo-adjuvant chemotherapy for advanced stage endometrial carcinoma: a glimmer of hope in select patients

Biocompatible porcine dermis graft to treat severe cystocele: impact on quality of life and sexuality

Green tea, black tea consumption and risk of endometrial cancer: a systematic review and meta-analysis

The paradigm shift in cervical cancer screening in Germany

The co-expression of GPER and Gankyrin in ovarian endometriosis and its correlation with the rASRM stages

Comment to the letter by Dr. S. Matsubara